Share this page!

Hilda Bastian, PhD Profile picture
Twitter logo
14 May, 4 tweets, 2 min read
Latest results for test-negative case-control study of Covid vax in US healthcare workers - & they get frequent testing.

March 18 data: 623 tested positive (cases) & 1,220 tested negative (controls). About a quarter Moderna vax, BNT-Pfizer the rest ...1/n cdc.gov/mmwr/volumes/7…
...You can see the protocol for this study here: cdc.gov/vaccines/covid… ...2/n
...Most of these healthcare professionals (HCPs) who got tested for Covid-19 were in roles that have substantial patient contact, most were aged 19-49, female, non-Hispanic white, underlying conditions that put them at risk if they got Covid-19 ...3/n
...Results: mRNA vaccines as effective as in the trials.

7 days or more after the 2nd dose, vaccination was 93.5% effective (CI 87–97).

(Adjusted = for age, race, & having underlying conditions)

So. much. relief.

4/4

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Hilda Bastian, PhD

Hilda Bastian, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @hildabast

Hilda Bastian, PhD Profile picture
14 May
This one's frustrating - I can't actually find the preprint, just the press release, so perhaps the preprint will answer some questions. It's claiming a 12-week delay of BNT-Pfizer is better than the 3-week prescribed interval. Several problems...1/n
...It's signs of immune response in a small group of people: 99 had the 3-week interval, 73 had the 12-week interval. 3 problems in that: small number, immune response not health outcome, & no mention of how the differences in the people were taken into account ...2/n
...Why is that a problem? Because we need to know whether who was the highest priority for the vax contributed to the observed results - the 3-week interval is how the rollout started the vax first. For example, ...3/4
Read 4 tweets
Hilda Bastian, PhD Profile picture
6 May
They've registered Sputnik Light in Russia, again on very thin data, again not waiting for phase 3. It's not a new vaccine: it's the 1st half of Sputnik V - an adenovirus 26 shot. Given the production problems since early on with the other half (Ad5)...1/n sputnikvaccine.com/newsroom/press…
...it's not surprising. (The Ad5 shot is the one there was a lot of controversy about recently because of replication-competence.) So it becomes a single-shot adenovirus vax (like J&J's & CanSino's) & it's half the price: full Sputnik V was expensive for Covid vax...2/n
...The data basis? 3 things: Immunogenicity results of a phase 1/2 trial with 110 people - some outcomes summarized in the press release only. Here's the trial register entry for it...3/n clinicaltrials.gov/ct2/show/NCT04…
Read 10 tweets
Hilda Bastian, PhD Profile picture
5 May
Results of an analysis of adverse events after Sputnik V vax in San Marino. From those vaccinated early, so some healthcare workers & mostly older people. Median age 68, so a much lower rate would be expected than for a general population ...1/n (Preprint) medrxiv.org/content/10.110…
...Everyone who got vaccinated was invited to participate, but it appears to have had a very low response rate: eg 1,946 out of 8,799 aged 60-89 did (22%): nothing reported to gauge how similar they were to those who didn't. Total group is 2,588, of whom 1,288 had both shots..2/n
...People were contacted 7 days after vaccination, then at 1 month & 3 months. So there would be more recall bias than in a trial with a diary method, but less recall bias at 7 days than for later data...3/n
Read 5 tweets
Hilda Bastian, PhD Profile picture
5 May
Oh my! Detail on adverse events in the Novavax UK trial included in a conference presentation - wish the numbers were there: definitely less than Moderna. Will need to blow this up & try to work it out! ...1/n novavax.com/sites/default/… HT @londonboyjohn
...A reminder of the vaccine efficacy rates for the phase 3 trial in the UK & the 2b efficacy trial in South Africa. It's an adjuvanted protein subunit vaccine...2/n
...They've made a booster aiming at the B.1.351 variant of concern. Here you see responses in baboons that had been immunized with the original a year ago. Bonus: you see with & without their adjuvant (same one used in the recently reported malaria vaccine) ...3/n
Read 5 tweets
Hilda Bastian, PhD Profile picture
5 May
Sinopharm's presentation on their Beijing vaccine to WHO's expert committee is now online: cdn.who.int/media/docs/def… 1/n HT @AlejandrodeBar1
...Includes this overview of preclinical toxicity studies. (Note, they've also published this study on some preclinical work tandfonline.com/doi/full/10.10…) ...2/n
...The phase 3, #4Humanity trial in the Middle East - here are the blood collections taken across all the countries. (No answer here to the question of whether there were regular tests for Covid-19 in the UAE part of the trial)...3/n
Read 12 tweets
Hilda Bastian, PhD Profile picture
3 May
The evidence assessments - but not the WHO decisions - for Sinopharm's Beijing vax & Sinovac's CoronaVac are going up on the WHO website who.int/news-room/even… HT @lutl88 @hvasquezhg ...1/n
...Sinopharm Beijing: WHO assessment. 45,000-participant trial in UAE/Bahrain/Egypt/Jordan, doses 21 days apart, efficacy:

- Overall: 78.1% (CI 65-86)
- For people with no previous infection: 80.8% (67-89) (the usual efficacy rate for others)

cdn.who.int/media/docs/def… ...2/n
...- Efficacy against hospitalization: 78.7% (CI 26-94)
- 1 death only, in the placebo group

But this is only up to age 60: negligible people over 60, & none had Covid-19 (in vax or placebo group)
...3/n
Read 25 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

Like this author's thread?

Get emails when @hildabast has new unrolls!

Check out other threads from @hildabast!

Read all threads by @hildabast

:(